Revumenib is a small molecule commercialized by Syndax Pharmaceuticals, with a leading Pre-Registration program in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to Globaldata, it is involved in 17 clinical trials, of which 13 are ongoing, and 4 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Revumenibs valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Revumenib is expected to reach an annual total of $717 mn by 2033 globally based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Revumenib Overview
Syndax Pharmaceuticals Overview
Syndax Pharmaceuticals (Syndax) is a biopharmaceutical company that discovers, develops and commercializes therapies for multiple cancer indications. The companys pipeline products include AUGMENT-101-2A for the treatment of R/R KMT2Ar acute lymphoblastic leukemia (ALL), AUGMENT-101-2B treats R/R KMT2Am acute myeloid eukemia (AML); AUGMENT-101-2C for R/R NPM1m Acute Myeloid Leukemia (AML); AUGMENT-102 targets R/R KMT2Ar and NPM1m acute leukemias; BEAT-AML for the treatment of Frontline KMT2Ar and NPM1m Acute Myeloid Leukemia (AML); INTERCEPT for MRD- progression in KMT2Ar and NPM1m acute myeloid leukemia (AML); Colorectal Cancer targets newly diagnosed NPM1m or KMT2Ar acute leukemias; AGAVE-201 treats chronic graft-versus-host disease (GVHD); Idiopathic Pulmonary Fibrosis for idiopathic pulmonary fibrosis. Syndax is headquartered in Waltham, Massachusetts, the US.
The operating loss of the company was US$230 million in FY2023, compared to an operating loss of US$151.8 million in FY2022. The net loss of the company was US$209.4 million in FY2023, compared to a net loss of US$149.3 million in FY2022.
For a complete picture of Revumenibs valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
